Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara(National Cancer Center Hospital East), Joaquín Guerra, Guillermo Lerzo, Juan Manuel O’Connor(Instituto Alexander Fleming), Merete Krogh, Mario Mandalà(University of Perugia), David Goldstein(New South Wales Department of Health), Eray Goekkurt(Sorbonne Université), Christian Caglevic, Xinqun Chen(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mustafa Özgüroğlu(Istanbul University-Cerrahpaşa), Atsushi Ohtsu(National Cancer Center Hospital East), Bettina Müller, Lene Bæksgaard, Felipe Rey(Dirección de Investigación y Desarrollo), Päivi Auvinen(University of Eastern Finland), Ángela R. Zambrano, Lorenzo Fornaro(Azienda Ospedaliera Universitaria Pisana), James Lynam, Markus Moehler(Johannes Gutenberg University Mainz), Tomasz Olesiński(The Maria Sklodowska-Curie National Research Institute of Oncology), Charles S. Fuchs(University of Southern California), Yung‐Jue Bang(Seoul National University), Thomas Seufferlein(Universität Ulm), Tuomo Alanko, Christos S. Karapetis(Clínica Alemana), Volker Kunzmann(University of Würzburg), Kei Muro(Aichi Cancer Center), Wasat Mansoor(The Christie NHS Foundation Trust), Maria Di Bartolomeo(Fondazione IRCCS Istituto Nazionale dei Tumori), Einat Shacham‐Shmueli(Sheba Medical Center), Niall C. Tebbutt(Austin Health), Scott Berry, Min‐Hee Ryu(Ulsan College), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Hyun Cheol Chung(Yonsei University), Andrus Magi, Andrew Strickland(Ghent University Hospital), Mette Yilmaz, Guillermo Ariel Mendez(Fundacion Favaloro Hospital Universitario), Mark Wong, Jean–Luc Van Laethem, Carlos Mayo(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mark Vincent, Soonmo Peter Kang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Paul L. Vasey(University of Lethbridge), Anneli Elme(North Estonia Medical Centre), Peter Thuss-Patience(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 1,315
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k